news
Crohn’s disease: discovery of two distinct molecular subtypes
By studying organoids derived from adult stem cells, researchers made a discovery that could improve the development of personalised therapeutics.
List view / Grid view
Targets
article
Unlocking the potential of smart antibodies
Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment.…
news
PolTREG begins CAR-Treg development for neuroinflammatory disease
After successful completion of the CAR-Treg preclinical study, the first in-human trial of the candidate to treat MS and ALS will commence.
news
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
news
Novel nasal spray effectively prevents influenza infection
The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans.
article
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
news
Anti-PD-1 autoantibody: a biomarker candidate for HCC
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
news
Largest biobank of sarcoma-patient-derived organoids to date
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
news
New monoclonal antibody drug could combat antimicrobial resistance
Scientists have developed a monoclonal antibody drug that could help to prevent infection from Acinetobacter baumannii.
article
Initial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
article
Drug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
news
BCL2 protein linked to metastatic castration-resistant prostate cancer
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
article
Overcoming operational challenges in CGT manufacturing with AI
In this Q&A, Dalip Sethi, scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio, discusses the integration of AI into CGT manufacturing processes to enhance operational efficiency and accelerate treatment access. He also elucidates the strategies that are being considered to overcome hurdles when implementing…
news
Damaged small intestine repaired with hPSC-derived organoids
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
news
New network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
